119 related articles for article (PubMed ID: 37625523)
1. A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
Guan J; Sun K; Guerrero CA; Zheng J; Xu Y; Mathur S; Teh BS; Farach A; Zhang J; Butler E; Pan PY; Zsigmond E; Mei Z; Mejia J; Chen SH; Chang JC; Bernicker EH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1531-1540. PubMed ID: 37625523
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Sun K; Xu Y; Zhang L; Niravath P; Darcourt J; Patel T; Teh BS; Farach AM; Guerrero C; Mathur S; Sultenfuss MA; Gupta N; Schwartz MR; Haley SL; Nair S; Li X; Nguyen TTA; Butner JD; Ensor J; Mejia JA; Mei Z; Butler EB; Chen SH; Bernicker EH; Chang JC
Clin Cancer Res; 2022 Oct; 28(20):4392-4401. PubMed ID: 35877117
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
Welsh J; Menon H; Chen D; Verma V; Tang C; Altan M; Hess K; de Groot P; Nguyen QN; Varghese R; Comeaux NI; Simon G; Skoulidis F; Chang JY; Papdimitrakopoulou V; Lin SH; Heymach JV
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051340
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B; Beardslee T; Khuri FR; Curran W; Lonial S; Waller EK; Ramalingam S; Owonikoko TK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428583
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
[TBL] [Abstract][Full Text] [Related]
7. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N; Tang Y; Teslenko I; Iannotti N
Cancer; 2022 Jan; 128(1):65-74. PubMed ID: 34478166
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
11. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
12. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
14. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
15. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P; Gong J; Zhang Y; Zhou S; Li Y; Han G; Meng R; Chen Y; Yang M; Shen Q; Chu Q; Xia S; Zhang P; Zhang L; Chen Y; Zhang L
Radiother Oncol; 2023 Jul; 184():109681. PubMed ID: 37105304
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
[TBL] [Abstract][Full Text] [Related]
17. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
Gray JE; Saltos A; Tanvetyanon T; Haura EB; Creelan B; Antonia SJ; Shafique M; Zheng H; Dai W; Saller JJ; Chen Z; Tchekmedyian N; Goas K; Thapa R; Boyle TA; Chen DT; Beg AA
Clin Cancer Res; 2019 Nov; 25(22):6623-6632. PubMed ID: 31409616
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
